Lymphocyte Biology: T and B Cell Activation
T cell activation (naïve CD4+/CD8+ T cell; TCR/CD3 complex (ITAM-Zap70 → LAT/SLP-76 → PLCγ1 → IP3/Ca2+ + DAG/PKCθ) + CD28 co-stimulation (B7-CD28 → PI3Kδ → Akt → mTORC1/mTORC2 → T cell metabolism/proliferation; also CD28 → Lck/ZAP70 amplification) → NFAT (Ca2+/calcineurin → NFAT Ser/Thr dephosphorylation → nuclear translocation → IL-2, IFN-γ, FASL) + NF-κB (PKCθ → CARMA1/BCL10/MALT1 → IKK → NF-κB → IL-2/TNF-α/IL-6) + AP-1 (Ras/ERK + JNK → c-Fos/c-Jun)); CD4+ Th polarisation: Th1 (IFN-γ/IL-12 → T-bet → IFN-γ; anti-intracellular); Th2 (IL-4/IL-13 → GATA-3 → IL-4/5/13; allergy); Th17 (IL-6/TGF-β/IL-23 → RORγt → IL-17A/F/IL-22; mucosal; autoimmune); Treg (TGF-β + IL-2 → FoxP3 → CD4+CD25+ iTreg; suppresses via IL-10/TGF-β/CTLA-4); B cell activation (BCR/CD19/CD21 → Btk/Lyn/Syk → PLCγ2/Ca2+ + NF-κB; T-dependent: CD40L (T cell)-CD40 (B cell) → class switch; BAFF/APRIL (B cell survival factors)); NK cells (innate; NKG2D/NKp30/46 activating receptors; KIR/CD94 inhibitory; missing self (MHC-I loss → NK activation); ADCC (CD16/FcγRIII); perforin/granzyme B cytotoxicity).
Spirulina Mechanisms in Lymphocyte Function
T Cell Activation and Th1/Th17 Balance
TCR/CD28 signalling (the T cell activation nexus; NFAT/NF-κB/AP-1 co-induction of IL-2 (T cell autocrine growth factor); CD28 → PI3K → mTOR → metabolic reprogramming (glycolysis ↑, OXPHOS ↓) for T cell proliferation; excessive T cell activation in autoimmunity/allergy) is modulated by spirulina: (1) NF-κB suppression (−30–45% IKKβ activation) → TCR-NF-κB pathway attenuation → reduced IL-2/TNF-α in over-stimulated T cells (LPS/anti-CD3 models); in physiological T cell activation (lower-level TCR stimulation by bona fide antigen): NF-κB suppression is partial, preserving effective immunity; (2) AMPK-mTOR axis: AMPK → mTORC1 suppression → T cell metabolic bias from glycolytic (effector) towards OXPHOS (memory/regulatory); AMPK activation favours Treg and memory T cell differentiation over effector hyper-activation; (3) Th17/RORγt suppression: phycocyanin → STAT3 (pTyr705) modulation (−15–25% phospho-STAT3 in IL-6/IL-23-stimulated T cells; RORγt is STAT3-dependent) → IL-17A −15–25% in Th17-polarising conditions; (4) Th1/T-bet: IFN-γ-producing Th1 cells (required for anti-viral/anti-intracellular bacterial immunity) are less suppressed by spirulina than Th17 (STAT3-dependent Th17 more sensitive to phycocyanin). Net: IL-17A/IL-23 axis −15–25%; IFN-γ (Th1/NK) modestly preserved or +5–10%.
Treg FoxP3 Expansion
FoxP3+ Treg (CD4+CD25+FoxP3+ regulatory T cells; the primary peripheral tolerance mechanism; differentiation requires: TGF-β1 (iTreg) + IL-2 (Treg survival/maintenance) → FoxP3 (fork-head box P3; the Treg master TF; acetylation at K31/K263 by CBP/p300 → FoxP3 stabilisation; deacetylation by SIRT1/HDAC6 → FoxP3 degradation); Treg suppression mechanisms: IL-10 (paracrine effector T cell suppression); TGF-β (contact-dependent); CTLA-4 (CD80/86 competition → reduced effector T cell co-stimulation); IL-2 consumption (CD25 IL-2R high-affinity); cAMP (PKA Ser/Thr phosphorylation of TCR signalling intermediates in effector T cells via gap junctions)) is expanded by spirulina through: (1) TGF-β1 contextual modulation (spirulina anti-inflammatory context → TGF-β1 maintained for iTreg induction while NF-κB-driven IL-6/IL-12 (Th17/Th1 cytokines competing with Treg) are suppressed; IL-6 blockade biases TGF-β towards FoxP3 Treg rather than RORγt Th17); (2) AMPK → Treg metabolic bias (AMPK → FAO-based metabolism favouring Treg differentiation; mTORC1 suppression prevents Th17 glycolytic switch); (3) Nrf2 → FoxP3 acetylation (CBP/p300 co-activation context; Nrf2 competes with NF-κB for p300 rather than SMAD3 in T cell context). CD4+CD25+FoxP3+ cells +10–20% in chronic inflammatory models (EAE, colitis) with spirulina supplementation.
NK Cell Activation and Cytotoxicity
NK cells (natural killer cells; innate lymphoid cells (ILC1-like); CD3−CD56+; ~5–15% of peripheral blood lymphocytes; activating receptors: NKG2D (MICA/MICB/ULBPs on stress/cancer cells → DAP10 → PI3K/Vav1 → actin polymerisation; cytotoxicity); NKp30/46 (NCR; viral haemagglutinin, tumour B7-H6); CD16 (FcγRIII; ADCC); inhibitory: KIR2DL/3DL (HLA-A/B/C → ITim signalling → inhibition); CD94/NKG2A (HLA-E → Csk/SHP-1 → inhibition); cytotoxicity: perforin (Ca2+-dependent pore formation in target cell membrane) + granzyme B (serine protease; caspase-3/7/9 activation → target cell apoptosis); cytokines: IFN-γ (early innate response; activates macrophages; enhances Th1); TNF-α; GM-CSF) are modulated by spirulina: (1) IL-12 augmentation: phycocyanin-polarised M1 macrophages produce IL-12 (+10–20%) → NK cell IFN-γ/cytotoxicity activation; (2) NKG2D ligand upregulation: Nrf2-driven stress response increases MICA/MICB on senescent/transformed cells (paradoxically beneficial for NK clearance of dysfunctional cells); (3) NK cell perforin/granzyme B expression: +10–20% in spirulina-supplemented subjects in some human studies (8 weeks, 3–5g/day); (4) NK cell CD56+CD69+ activation marker: +10–15%. Anti-tumour NK surveillance enhanced without autoimmune activation (no self-cell MHC-I loss → no NK kill of healthy cells).
B Cell IgA/IgM and Mucosal Immunity
B cell class switching (IgM → IgG/IgA/IgE; CD40L-CD40 + cytokines: IL-4/13 → IgG1/IgE switch; TGF-β/IL-5 → IgA switch (AID (activation-induced cytidine deaminase) → switch recombination); IgA1/2 (mucosal; secretory IgA (SIgA) = dimer + J-chain + secretory component; primary mucosal defence (gut/respiratory tract)); IgM (first response; complement activation); BAFF (B cell-activating factor; TNFSF13b; survival signal for transitional/mature B cells; upregulated by IFN-α/β and NF-κB; excessive BAFF → autoreactive B cell survival → SLE/RA) regulation by spirulina: (1) IgA support: phycocyanin augments gut mucosal IgA (sIgA +15–25% in animal models; Peyer's patch B cell activation via DC IL-10 → IgA class switch → gut barrier protection); (2) IgG1/IgE allergic antibody: IL-4/Th2 suppression (−10–20% GATA-3/IL-4 in Th2-skewed allergy models) → reduced IgE class switch → anti-allergic effect; (3) BAFF: NF-κB suppression → BAFF −10–20% → reduced autoreactive B cell survival; (4) B cell NF-κB: BCR → CARMA1/Malt1/BCL10 → IKK → NF-κB; suppressed by spirulina → attenuated auto-antibody production in autoimmune models.
Clinical Outcomes in Lymphocyte Function
- NK cell cytotoxicity (K562 target; perforin/granzyme): +10–20%
- CD4+CD25+FoxP3+ Treg (peripheral blood): +10–20%
- IL-17A (Th17; serum; inflammatory conditions): −15–25%
- IFN-γ (Th1/NK; anti-viral; preserved/enhanced): +5–15%
- sIgA (secretory; gut/saliva mucosal): +15–25%
- IgE (total; atopic/allergic subjects): −10–20%
Dosing and Drug Interactions
Immune modulation (autoimmune prevention/mucosal immunity): 3–8g daily; higher doses (8–10g) for cancer immune surveillance support. Immunosuppressants (cyclosporine/tacrolimus; calcineurin inhibitors): Spirulina Treg expansion could reduce auto-reactive T cell activation complementing calcineurin inhibitor T cell suppression; monitor for over-immunosuppression in solid organ transplant. Biologics (anti-TNF, anti-IL-17): Spirulina IL-17A −15–25% is modest vs. pharmaceutical IL-17A blockade (ixekizumab: >90% IL-17A suppression); spirulina is adjunctive not substitutive. Checkpoint inhibitors (PD-1/CTLA-4 blockade): Spirulina NK cell activation (+10–20%) could enhance anti-tumour immunity synergistically with checkpoint inhibition; Treg expansion (spirulina) could theoretically dampen checkpoint inhibitor efficacy — clinical significance unknown. Allergy medications (antihistamines): Spirulina IgE/IL-4/Th2 attenuation: complementary to antihistamine symptom control. Summary: NK cytotoxicity +10–20%, IL-17A −15–25%, Treg +10–20%, sIgA +15–25%; dosing 3–8g daily. NK concern: low (monitor with immunosuppressant co-use).